111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
通过 BCL-3 介导的 PD-L1 表达，DC-SIGN+肿瘤相关巨噬细胞在结直肠癌免疫逃逸和进展中起关键作用
Authors Zhang J, Zhao Y , Wang X, Miao C, Xu W, Wan C, Hu B , Qian F
Received 20 August 2025
Accepted for publication 2 December 2025
Published 10 December 2025 Volume 2025:14 Pages 1395—1410
DOI https://doi.org/10.2147/ITT.S562182
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Michael Shurin
Jianfeng Zhang,1,* Yifan Zhao,1,* Xingchao Wang,1,2 Chuang Miao,1 Wangcheng Xu,1 Chunhua Wan,3 Baoying Hu,1 Fei Qian1
1Department of General Surgery, Affiliated Hospital of Nantong University & Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China; 2Department of General Surgery Heze City Hospital, Heze, 274000, People’s Republic of China; 3School of Public Health, Nantong University, Nantong, 226001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Fei Qian, Department of General Surgery, Affiliated Hospital of Nantong University & Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China, Tel +86 513 8505 1893, Email qianfeint@163.com Baoying Hu, Department of General Surgery, Affiliated Hospital of Nantong University & Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China, Tel +86 513 8505 1893, Email huby86@ntu.edu.cn
Background: Tumor-associated macrophages (TAMs) play a pivotal role in facilitating tumor immune escape in colorectal cancer (CRC). C-type lectin Dendritic Cell-Specific ICAM-Grabbing Nonintegrin (DC-SIGN) is variably expressed in TAMs in tumor tissues. However, its role in CRC progression remains poorly defined.
Methods: We analyzed The Cancer Genome Atlas (TCGA) data and an independent CRC cohort to evaluate the prognostic significance of DC-SIGNhigh TAMs. Immunofluorescence and flow cytometry were used to characterize DC-SIGN expression in CRC tissues. RNA sequencing and bioinformatics analyses were performed on sorted DC-SIGNhigh and DC-SIGNlow TAMs. Functional assays using THP-1–derived macrophages and primary TAMs were conducted to examine how DC-SIGN regulates PD-L1 expression via the transcription factor BCL-3.
Results: DC-SIGN was specifically expressed in TAMs within CRC tissues and was associated with increased stromal and immune cell infiltration. DC-SIGN expression correlated with worsened prognosis in CD8high, but not CD8low, patients with CRC across two independent cohorts, and served as an independent predictor of unfavorable survival in CD8high CRC. Transcriptomic profiling revealed that DC-SIGNhigh TAMs exhibited distinct immune-related pathways, including marked upregulation of PD-L1 and PD-L1 immune checkpoint pathway. Mechanistically, Lewisx-ligated DC-SIGN upregulated PD-L1 expression at both mRNA and protein levels through BCL-3, which directly bound to the PD-L1 promoter.
Conclusion: The DC-SIGN/BCL-3 axis in TAMs drives PD-L1 expression and contributes to CRC immune evasion. Targeting DC-SIGN+ TAMs may represent a promising therapeutic strategy to reprogram the tumor microenvironment (TME) and improve the efficacy of immunotherapy in CRC.
Plain Language Summary: Colorectal cancer is one of the most common cancers, and while the immune system is designed to recognise and destroy cancer cells, tumours can develop ways to avoid this attack. In this study, we investigated immune cells called macrophages, which normally protect the body but can be reprogrammed inside tumours to support cancer growth. We found that a molecule called DC-SIGN is present on many of these macrophages in colorectal cancer and that patients with higher levels of these DC-SIGN–positive macrophages had poorer outcomes, particularly when their tumours also contained many cancer-fighting T cells. By studying these cells in detail, we discovered that DC-SIGN increases the production of PD-L1, a protein that blocks T cells from killing cancer cells. We also showed that DC-SIGN uses another protein, BCL-3, as a switch to turn on PD-L1. These findings reveal a new way that colorectal cancer avoids the immune system and suggest that targeting DC-SIGN may help improve immunotherapy, a treatment that boosts the body’s natural defences against cancer.
Keywords: colorectal cancer, tumor-associated macrophages, C-type lectin dendritic cell-specific ICAM-grabbing nonintegrin, programmed cell death ligand-1, BCL-3, immune evasion
1Department of General Surgery, Affiliated Hospital of Nantong University & Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China; 2Department of General Surgery Heze City Hospital, Heze, 274000, People’s Republic of China; 3School of Public Health, Nantong University, Nantong, 226001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Fei Qian, Department of General Surgery, Affiliated Hospital of Nantong University & Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China, Tel +86 513 8505 1893, Email qianfeint@163.com Baoying Hu, Department of General Surgery, Affiliated Hospital of Nantong University & Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China, Tel +86 513 8505 1893, Email huby86@ntu.edu.cn
Background: Tumor-associated macrophages (TAMs) play a pivotal role in facilitating tumor immune escape in colorectal cancer (CRC). C-type lectin Dendritic Cell-Specific ICAM-Grabbing Nonintegrin (DC-SIGN) is variably expressed in TAMs in tumor tissues. However, its role in CRC progression remains poorly defined.
Methods: We analyzed The Cancer Genome Atlas (TCGA) data and an independent CRC cohort to evaluate the prognostic significance of DC-SIGNhigh TAMs. Immunofluorescence and flow cytometry were used to characterize DC-SIGN expression in CRC tissues. RNA sequencing and bioinformatics analyses were performed on sorted DC-SIGNhigh and DC-SIGNlow TAMs. Functional assays using THP-1–derived macrophages and primary TAMs were conducted to examine how DC-SIGN regulates PD-L1 expression via the transcription factor BCL-3.
Results: DC-SIGN was specifically expressed in TAMs within CRC tissues and was associated with increased stromal and immune cell infiltration. DC-SIGN expression correlated with worsened prognosis in CD8high, but not CD8low, patients with CRC across two independent cohorts, and served as an independent predictor of unfavorable survival in CD8high CRC. Transcriptomic profiling revealed that DC-SIGNhigh TAMs exhibited distinct immune-related pathways, including marked upregulation of PD-L1 and PD-L1 immune checkpoint pathway. Mechanistically, Lewisx-ligated DC-SIGN upregulated PD-L1 expression at both mRNA and protein levels through BCL-3, which directly bound to the PD-L1 promoter.
Conclusion: The DC-SIGN/BCL-3 axis in TAMs drives PD-L1 expression and contributes to CRC immune evasion. Targeting DC-SIGN+ TAMs may represent a promising therapeutic strategy to reprogram the tumor microenvironment (TME) and improve the efficacy of immunotherapy in CRC.
Plain Language Summary: Colorectal cancer is one of the most common cancers, and while the immune system is designed to recognise and destroy cancer cells, tumours can develop ways to avoid this attack. In this study, we investigated immune cells called macrophages, which normally protect the body but can be reprogrammed inside tumours to support cancer growth. We found that a molecule called DC-SIGN is present on many of these macrophages in colorectal cancer and that patients with higher levels of these DC-SIGN–positive macrophages had poorer outcomes, particularly when their tumours also contained many cancer-fighting T cells. By studying these cells in detail, we discovered that DC-SIGN increases the production of PD-L1, a protein that blocks T cells from killing cancer cells. We also showed that DC-SIGN uses another protein, BCL-3, as a switch to turn on PD-L1. These findings reveal a new way that colorectal cancer avoids the immune system and suggest that targeting DC-SIGN may help improve immunotherapy, a treatment that boosts the body’s natural defences against cancer.
Keywords: colorectal cancer, tumor-associated macrophages, C-type lectin dendritic cell-specific ICAM-grabbing nonintegrin, programmed cell death ligand-1, BCL-3, immune evasion